Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasmsBenjamin H. Durham, Omar Abdel‐Wahab, Estibaliz Lopez Rodrigo et al.|Nature Medicine|2019Cited by 228
Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium StudyRishi Lulla, Maryam Fouladi, Linda R. Bressler et al.|Neuro-Oncology|2016Cited by 140